Cite
HARVARD Citation
Aix, S. et al. (2023). Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet. 11 (1), pp. 74-86. [Online].